1,779 reports of this reaction
3.1% of all PROPOFOL reports
#4 most reported adverse reaction
CARDIAC ARREST is the #4 most commonly reported adverse reaction for PROPOFOL, manufactured by Fresenius Kabi USA, LLC. There are 1,779 FDA adverse event reports linking PROPOFOL to CARDIAC ARREST. This represents approximately 3.1% of all 57,130 adverse event reports for this drug.
PROPOFOL has an overall safety score of 95 out of 100. Patients taking PROPOFOL who experience cardiac arrest should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CARDIAC ARREST is moderately reported among PROPOFOL users, representing a notable but not dominant share of adverse events.
In addition to cardiac arrest, the following adverse reactions have been reported for PROPOFOL:
The following drugs have also been linked to cardiac arrest in FDA adverse event reports:
CARDIAC ARREST has been reported as an adverse event in 1,779 FDA reports for PROPOFOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
CARDIAC ARREST accounts for approximately 3.1% of all adverse event reports for PROPOFOL, making it a notable side effect.
If you experience cardiac arrest while taking PROPOFOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.